PTGX Protagonist Therapeutics, Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1377121 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY163.7%
TTM net income YoY645.5%
TTM EPS YoY616.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin58.6%
Net margin62.0%
FCF margin19.8%
EBITDA margin58.9%
Returns
ROE39.6%
ROA37.0%
ROIC (approx.)56.5%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets5.4%
Debt / equity0.00x
Current ratio19.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio25.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $46.02M | $434.43M |
| R&D expense | $159.29M | $138.13M |
| SG&A expense | $44.85M | $43.46M |
| Operating income | -$158.13M | $252.84M |
| Pretax income | -$129.31M | $279.41M |
| Income tax | $838,000 | $4.22M |
| Net income | -$130.15M | $275.19M |
| EBITDA | -$156.85M | $253.67M |
| EPS (basic) | -2.05 | 4.47 |
| EPS (diluted) | -2.05 | 4.23 |
| Weighted avg. shares (diluted) | 63.57M | 65.08M |
| Balance sheet | ||
| Cash & equivalents | $128.39M | $97.47M |
| Short-term investments | $438.97M | $321.66M |
| Current assets | $577.57M | $591.64M |
| PP&E, net | $3.86M | $3.19M |
| Total assets | $668.19M | $744.73M |
| Current liabilities | $45.44M | $47.40M |
| Total liabilities | $53.48M | $69.43M |
| Shareholders' equity | $614.71M | $675.29M |
| Shares outstanding | 62.58M | 61.04M |
| Cash flow statement | ||
| Operating cash flow | $57.67M | $184.15M |
| Capital expenditure | $1.59M | $1.35M |
| Free cash flow | $56.08M | $182.80M |
| Investing cash flow | -$49.33M | -$299.48M |
| Financing cash flow | $22.86M | $25.85M |
| Depreciation & amortization | $1.28M | $826,000 |
| Stock-based compensation | $45.97M | $37.55M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.